Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in India

Non-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patients who do not consume alcohol or take it in insignificant amounts, but have risk factors such as overweight or obesity, diabetes mellitus (high blood sugar), hypertension (high blood pressure) or dyslipidemia (abnormal blood lipids).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news